Skip to main content

Funktionelle Durchblutungsstörungen

  • Chapter
  • First Online:
  • 379 Accesses

Part of the book series: Springer Reference Medizin ((SRM))

Zusammenfassung

Den Begriff funktionelle Durchblutungsstörungen verwendet man für Krankheitsbilder, bei denen es zu einer Engstellung oder Erweiterung der Gefäße kommt, ohne dass organische Gefäßveränderungen vorhanden sind.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   389.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Allen EV, Brown GE (1932) Raynaud’s disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 183(2):187–200

    Article  Google Scholar 

  • Baldwin ZK, Ceraldi CC (2003) Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg 37(3):676–678

    Article  Google Scholar 

  • Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, Prentice CR (1983) Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome: a double-blind controlled trial. Lancet 1:313–315

    Article  CAS  Google Scholar 

  • Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21(3):244–250

    Article  CAS  Google Scholar 

  • Bollinger A, Schlumpf M (1976) Finger blood flow in healthy subjects of different age and sex and in patients with primary Raynaud’s disease. Acta Chir Scand Suppl 465:42–47

    CAS  PubMed  Google Scholar 

  • Bollinger A, Mahler F, Meier B (1977) Velocity patterns in nailfold capillaries of normal subjects and patients with Raynaud’s disease and acrocyanosis. Bibl Anat 16:142–145

    Google Scholar 

  • Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud’s disease. Arch Intern Med 166(2):231–233

    Article  CAS  Google Scholar 

  • Coffman JD, Cohen RA (1988) Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 18(3):309–313

    Article  CAS  Google Scholar 

  • Dowd PM, Martin MF, Cooke ED, Bowcock SA, Jones R, Dieppe PA, Kirby JD (1982) Treatment of Raynaud’s phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 106(1):81–89

    Article  CAS  Google Scholar 

  • Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655

    Article  CAS  Google Scholar 

  • Eadie MJ (2001) Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 15(2):105–118

    Article  CAS  Google Scholar 

  • El Menyar AA (2006) Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. J Postgrad Med 52(1):51–56

    PubMed  Google Scholar 

  • Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D (2007) The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud’s phenomenon. Clin Pharmacol Ther 81(4):503–509

    Article  CAS  Google Scholar 

  • Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985

    Article  CAS  Google Scholar 

  • Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R (2001) Treatment of Raynaud’s phenomenon with intravenous prostaglandin E1 alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 28(4):786–794

    CAS  PubMed  Google Scholar 

  • Herskowitz MM, Gillego V, Ward M, Wright G (2002) Cocaine-induced mesenteric ischemia: treatment with intra-arterial papaverine. Emerg Radiol 9(3):172–174

    Article  Google Scholar 

  • Hirschl M, Katzenschlager R, Francesconi C, Kundi M (2004) Low level laser therapy in primary Raynaud’s phenomenon – results of a placebo controlled, double blind intervention study. J Rheumatol 31(12):2408–2412

    PubMed  Google Scholar 

  • Husmann MJ, Barton M, Jacomella V, Silvestro V, Amann-Vesti B (2006) Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis. J Vasc Surg 44(5):993–997

    Article  Google Scholar 

  • Jamieson GG, Ludbrook J, Wilson A (1971) Cold hypersensitivity in Raynaud’s phenomenon. Circulation 44:254–264

    Article  CAS  Google Scholar 

  • Kuhnert SM, Phillips WJ, Davis MD (1999) Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 135(12):1447–1449

    Article  CAS  Google Scholar 

  • Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19(9):1403–1406

    CAS  PubMed  Google Scholar 

  • LeRoy EC, Medsger TA (1992) Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 10(5):485–488

    CAS  PubMed  Google Scholar 

  • Levien TL (2006) Phosphodiesterase inhibitors in Raynaud’s phenomenon. Ann Pharmacother 40(7–8):1388–1393

    Article  CAS  Google Scholar 

  • Maga P, Kuzdzal J, Nizankowski R, Szczeklik A, Sladek K (2007) Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. J Thorac Cardiovasc Surg 133(6):1428–1433

    Article  Google Scholar 

  • Mahler F, Meier B, Frey R, Bollinger A, Anliker M (1977) Reaction of red blood cell velocity in nailfold capillaries to local cold in patients with vasospastic disease. Bibl Anat 16:155–158

    Google Scholar 

  • Mahler F, Saner H, Boss CH, Annaheim M (1987) Local cold exposure for capillaroscopic examination of patients with Raynaud’s syndrome. Microvasc Res 33:422–427

    Article  CAS  Google Scholar 

  • Maricq HR, Spencer-Green G, LeRoy EC (1975) Abnormal capillary patterns and systemic disease in scleroderma (progressive systemic sclerosis). Bibl Anat 13:248–249

    CAS  PubMed  Google Scholar 

  • Maricq HR, LeRoy EC, D'Angelo WA, Medsger TA, Rodnan GP, Sharp GC, Wolfe JF (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23(2):183–189

    Article  CAS  Google Scholar 

  • Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25(2):153–158

    Article  Google Scholar 

  • Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298:561–564

    Article  CAS  Google Scholar 

  • Riccardi MT, Chialà A, Lannone F, Grattagliano V, Covelli M, Lapadula G (2007) Treatment of digital ulcers in systemic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 59(2):135–139

    CAS  PubMed  Google Scholar 

  • Rusch NJ, Shepherd JT, Vanhoutte PM (1981) The effect of profound cooling on adrenergic neurotransmission in canine cutaneous veins. J Physiol 311:57–65

    Article  CAS  Google Scholar 

  • Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, Dowd PM (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol 117(6):751–758

    Article  CAS  Google Scholar 

  • Smith CD, McKendry RVR (1982) Controlled trial of nifedipine in the treatment of Raynaud’s phenomon. Lancet 2:1299–1301

    Article  CAS  Google Scholar 

  • Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C (1987) Treatment of Raynaud’s phenomenon with captopril. Drugs Exp Clin Res 13(1):37–42

    CAS  PubMed  Google Scholar 

  • Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Beatrice Amann-Vesti .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Amann-Vesti, B. (2020). Funktionelle Durchblutungsstörungen. In: Debus, E., Gross-Fengels, W. (eds) Operative und interventionelle Gefäßmedizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-53380-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-53380-2_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-53378-9

  • Online ISBN: 978-3-662-53380-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics